MSH activity in plasma and pituitaries of rats after various treatments

Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia

Major problem involved in treatment of chronic pain with morphine is the development of tolerance and dependence. Previous studies have demonstrated the participation of melanocortin (MC) system in the development of tolerance to antinociceptive effect of morphine. However, the impact of supraspinal MC4 receptors (MC4 R) modulation on this phenomenon and morphine withdrawal hyperalgesia remained unexplored. We investigated the role of central MC4 R in acute, chronic effects and withdrawal reactions of morphine using tail flick test. Acute intracerebroventricular (icv) administration of morphine (2-20 microg/rat) exhibited antinociceptive activity, which was antagonized by subeffective dose of nonselective MC R agonist NDP-MSH (0.04 ng/rat, icv), and potentiated by subeffective dose of MC4 R antagonist HS014 (0.008 ng/rat, icv). Isobolographic analysis revealed antagonistic interaction between NDP-MSH and morphine, and additive interaction between HS014 and morphine combinations. While chronic icv infusion of morphine (20 ng/microl/h) via osmotic pump for 7 days developed tolerance to its antinociceptive effect, its discontinuation produced hyperalgesia. Co-administration of HS014 (0.008 ng/rat, icv) with chronic morphine not only delayed the development of tolerance but also prevented withdrawal hyperalgesia. Furthermore, acute treatment with HS014 (0.008 and 0.04 ng/rat, icv) dose dependently attenuated the withdrawal hyperalgesia. This suggests the involvement of central MC4 R in the mechanism of development of tolerance and dependence following chronic morphine administration. We speculate that targeting this receptor may be a novel strategy to improve the effectiveness of morphine in the treatment of chronic pain.

The effect of morphine on MC4 and CRF receptor mRNAs in the rat amygdala and attenuation of tolerance after their blockade

The relationships between the CRF, which enhances the proopiomelanocortin (POMC) biosynthesis, and POMC-derived peptides (opioids and melanocortins) might be a new target for rational treatment of morphine tolerance. In the present study, we investigated the effect of acute and chronic morphine administration on the level of CRF1 and melanocortin 4 receptor (MC4-R) mRNAs in the rat amygdala by quantitative real-time PCR method. Moreover, we investigated the effect of antagonists of melanocortin and CRF receptors, SHU9119 and alpha-helical CRF (alphah-CRF), respectively, administered bilaterally into the central nucleus of the amygdala, on morphine tolerance using tail-flick and paw withdrawal tests. Our study demonstrated that acute morphine administration decreased the level of MC4-R mRNA in the rat amygdala. This decrease was attenuated following chronic morphine administration, and mRNA level of MC4 receptors was gradually increased and, on 9th day of morphine administration, i.e. in the period when morphine tolerance already developed, the level was significantly increased in comparison with control and with the effect after single morphine dose. In contrast, morphine did not affect the CRF receptor. In behavioral study, we demonstrated that SHU9119 and alphah-CRF significantly increased the antinociceptive effect of morphine, when they were injected into the amygdala prior to morphine administration in tolerant rats. We have shown for the first time the contribution of amygdalar melanocortin receptors to morphine tolerance, and we conclude that the altered melanocortin receptor function may play an important role in the development of morphine-induced tolerance. CRF and melanocortin peptides can modulate the phenomena in the same direction, in opposition to opioids. Therefore, antagonists of melanocortin receptors may be regarded as possible therapeutic modulators of morphine tolerance.

Mu and delta opioid receptor regulation of pro-opiomelanocortin peptide secretion from the rat neurointermediate pituitary in vitro

We investigated the ability of selective opioid agonists and antagonists to influence pro-opiomelanocortin peptide secretion from the rat neurointermediate lobe in vitro. The mu-opioid agonist DAMGO ([D-Ala(2), N-Me-Phe(4), Gly(5)-ol]enkephalin) significantly stimulated beta-endorphin and alpha-melanocyte-stimulating hormone release relative to controls early (30 min) in the incubation period. Similar effects on beta-endorphin secretion were observed with the selective mu-opioid agonist dermorphin. The delta-opioid receptor agonist DPDPE ([D-Pen(2,5)]enkephalin) weakly inhibited beta-endorphin secretion relative to controls while the kappa-opioid receptor agonist U50488 had no effect. The mu-opioid selective antagonist CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2)) inhibited basal beta-endorphin secretion while kappa- and delta-opioid receptor antagonists had no effect. Our data support a role for local mu-opioid receptor control of intermediate lobe pro-opiomelanocortin peptide secretion. Peptide secretion from melanotropes appears to be tonically stimulated by activation of mu-opioid receptors in the absence of intact neuronal innervation to the intermediate lobe.

alpha-melanocyte-stimulating hormone and habituation of prey-catching behavior in the Texas toad, Bufo speciosus

We investigated dose-dependent effects of alpha-melanocyte-stimulating hormone (alpha-MSH) on habituation in the Texas toad, Bufo speciosus. Additionally, we determined changes in plasma and brain levels of alpha-MSH following peripheral administration of the peptide or following exposure to an ether stressor. The ability of alpha-MSH to facilitate acquisition of habituation was dose dependent. Plasma alpha-MSH concentrations were elevated within 5 min of dorsal lymph sac injection and remained elevated up to 600% over controls after 30 min. Administration of 50 microgram alpha-MSH had no effect on plasma corticosterone levels. Radiolabeled alpha-MSH was detected in cerebrospinal fluid microdialysates within minutes of peripheral injection. Concentrations of alpha-MSH in the telencephalon and preoptic area were significantly lowered after ether exposure, whereas levels in the optic tectum, thalamus/hypothalamus, brainstem, and plasma were unchanged. We conclude that alpha-MSH administered peripherally facilitates habituation in a dose-dependent fashion. Our results confirm that the effects of alpha-MSH are independent of corticosterone secretion. The peptide is cleared rapidly into the bloodstream and enters the cerebrospinal fluid after dorsal lymph sac injection. Neuronal alpha-MSH may help toads gather information about their environment when exposed to certain stressors.

Reversal of alexia in multiple sclerosis by weak electromagnetic fields

The occurrence of cognitive deficits in patients with multiple sclerosis (MS) has been recognized since 1877 when Charcot first observed "enfeeblement of memory" in his patients. Cognitive deficits have been reported in almost 50% of patients with a relapsing-remitting course and in a significantly higher percentage of patients with a chronic progressive course leading to intellectual disability which is often severe enough to preclude employment. MS is considered a form of subcortical dementia and the occurrence of classical cortical disorders such as aphasia, agnosia and apraxia is reported to be rare in the disease. However, in my experience alexia, a reading impairment unrelated to visual acuity or visual field defects, is common in patients with MS. Recently, I reported that treatment with picotesla range electromagnetic fields (EMFs) is an efficacious modality in the management of both the motor and cognitive symptoms of MS. Three patients with MS who developed alexia as a manifestation of the disease are presented. In all patients the alexia was reversed several months after they began treatment with EMFs. Since alexia usually reflects a disconnection syndrome whereby lesions involving the left visual cortex and the splenium of the corpus callosum disconnect language association areas from visual association areas, it is suggested that reversal of the alexia in these patients by EMFs was related to improved interhemispheric transcallosal transmission of visual information. In addition, it is conceivable that changes in the metabolism of monoamines, which are involved in visual information processing and reading comprehension, may have been important in causing reversal of the alexia. This report further supports the unique efficacy of this treatment modality in reversing specific cognitive deficits in MS.

Multiple sclerosis: improvement of visuoperceptive functions by picoTesla range magnetic fields

The occurrence of cognitive deficits in multiple sclerosis (MS) has been recognized since 1877 when Charcot first observed "enfeeblement of memory" in his patients. Recent studies employing standardized neuropsychological tests have confirmed the high incidence of cognitive deficits in MS patients particularly those with a chronic progressive course of the disease. Visuoperceptive and visuomotor deficits commonly occur in MS patients and are thought to reflect damage to attentional systems due to interruption by demyelinating plaques of nerve conduction along the ascending projections from the brainstem reticular formation to the cortex. Impairment of synaptic conductivity due to serotoninergic depletion (5-HT) may contribute to the emergence of cognitive deficits in MS. The present communication concerns a 36 year old patient with MS in whom external application of picoTesla range magnetic fields (MF) resulted in rapid improvement of symptoms including visuoperceptive functions as demonstrated on various drawing tasks. The report confirms the efficacy of picoTesla range MF in the treatment of MS and demonstrates beneficial effects on cognitive functions as well.

Reversal of visual neglect in Parkinson's disease by treatment with picoTesla range magnetic fields

Visual neglect and impairment in perceptual motor or visuospatial tasks are among the most frequently encountered abnormalities in neuropsychological testing of patients with Parkinson's disease, being present in up to 90% of patients. It has been proposed that neglect reflects an attentional-arousal deficit induced by lesions that interrupt a cortical-limbic-reticular loop. Recently, we have reported that application of extracranial magnetic fields (MF) in the picoTesla range was efficacious in reducing the severity of the motor disability of Parkinsonism as well as improving some of the cognitive abnormalities associated with the disease such as visuoperceptive deficits. We now present a 61 year old fully medicated Parkinsonian patient in whom rapid reversal of left visual neglect as well as improvement in visuoconstructional (drawing) performance was noted immediately after a single external application of MF. We propose that this effect was related to enhancement of directed attention through a mechanism involving an interaction between the pineal gland, which is considered a "magnetosensor," and the reticular formation which mediates arousal and attention. This report demonstrates the efficacy of extremely weak MF in reversing some of the cognitive abnormalities in Parkinsonism, notably neglect and visuoperceptive deficits, which contribute significantly to impairment of the patient's daily living activities.

Effects of the enkephalin analog (D-Met2,Pro5)-enkephalinamide on alpha-melanocyte-stimulating hormone secretion

We used the met-enkephalin analog (D-Met2,Pro5)-enkephalinamide (DMPEA) to investigate enkephalinergic control of alpha-melanocyte-stimulating hormone (alpha-MSH) secretion. Systemic (s.c.) administration of DMPEA elevated plasma titers of alpha-MSH in a dose- and time-related manner. Pretreatment with the opiate antagonist naltrexone had no effect on basal plasma levels of alpha-MSH but blocked DMPEA-induced alpha-MSH release. Treatment with a dose of naltrexone sufficient to block DMPEA-induced secretion of alpha-MSH had no effect on stress-induced secretion of alpha-MSH. Although pretreatment with the dopamine receptor agonist apomorphine prevented DMPEA-induced alpha-MSH secretion, DMPEA had no effect on the synthetic activity of tuberohypophysial dopamine neurons as gauged by measuring the accumulation of 3,4-dihydroxyphenylalanine in the neurointermediate lobe (NIL) following administration of NSD-1015. In vitro treatment of isolated NILs with DMPEA resulted in a significant increase in alpha-MSH release. Naltrexone completely blocked the stimulatory effects of DMPEA on alpha-MSH release in vitro. Our results indicate that DMPEA stimulates alpha-MSH secretion by acting directly through opiate receptors at the level of the NIL.

Rapid improvement of visuoperceptive functions by picoTesla range magnetic fields in patients with Parkinson's disease

Impairment in perceptual motor or visuospatial tasks is among the most frequently encountered abnormality in neuropsychological testing of patients with Parkinson's disease, being present in up to 90% of cases. Visuoperceptive deficits can result from cortical and subcortical lesions involving the right hemisphere, thalamus, and basal ganglia and are thought to reflect a defect in attentional-arousal mechanisms induced by lesions that interrupt a cortical-limbic-reticular activating loop. Clinically, the presence of visuoperceptive impairment may not be noted by Parkinsonian patients but may contribute to various disabilities including difficulty driving a vehicle and difficulties performing daily tasks which require intact visuospatial abilities (i.e., walking, dressing, drawing and copying designs). The present communication concerns two fully medicated Parkinsonian patients who responded to extracranial treatment with picoTesla range magnetic fields (MF), behaviorally and also demonstrated rapidly and dramatically enhanced visuoperceptive functions as demonstrated on various drawing tasks. These findings demonstrate the efficacy of extremely weak MF in enhancing cognitive functions in patients with Parkinson's disease.

Distribution of Met5-enkephalin-Arg6-Gly7-Leu8-immunoreactivity in the rat and mouse pituitary gland

The distribution of the octapeptide Met5-enkephalin-Arg6-Gly7-Leu8 (MEAGL), a proenkephalin A-derived opioid peptide, in the rat and mouse pituitary gland was studied using the indirect immunofluorescence technique and immunoelectron microscopy. The anterior lobe contained a few MEAGL-immunoreactive cells but no nerve fibers. A previously unknown enkephalin-immunoreactive nerve fiber system was revealed in the intermediate lobe. These fibers originated in a dense MEAGL-immunoreactive plexus located along the border between the intermediate and posterior lobes and were distributed throughout the lobe. In the posterior lobe, MEAGL immunoreactivity was found in a very dense network of varicose fibers that was evenly distributed over the entire lobe. These results provide a morphological correlate for previous chemical studies and together with them suggest that MEAGL-immunoreactive innervation regulates endocrine functions of the intermediate and posterior lobes directly at the pituitary level.

Abnormal pituitary function during melancholia: reduced alpha-melanocyte-stimulating hormone secretion and increased intact ACTH non-suppression

In order to investigate pituitary alpha-melanocyte-stimulating hormone (alpha-MSH), intact (1-39 structure) adrenocorticotropic hormone (ACTH), and adrenal cortisol secretion, we measured 8 a.m. plasma levels of those hormones before and after administration of 1 mg dexamethasone in 39 depressed inpatients and 10 healthy controls. We found a significantly lower baseline alpha-MSH secretion in melancholic patients as opposed to healthy controls. There were no significant relations between alpha-MSH secretion on the one hand and ACTH or cortisol secretion on the other. Dexamethasone did not affect the 8 a.m. alpha-MSH circulating levels. The post-dexamethasone intact ACTH and cortisol values were significantly higher in melancholics as compared with healthy, minor and simple major depressed subjects. ACTH non-suppression was defined as post-dexamethasone intact ACTH greater than or equal to 12 pg/ml. ACTH non-suppression was found to be more sensitive (70%) and specific (100%) for melancholia than cortisol non-suppression. By means of pathway analysis we have established that cortisol non-suppression during a severe depression is completely determined by an augmented ACTH escape from suppression by dexamethasone. It is concluded that the assay of post-dexamethasone intact ACTH could, in the future, replace post-dexamethasone cortisol determination.

Dexamethasone facilitates release of the neuropeptide alpha-MSH

alpha-Melanocyte stimulating hormone (alpha-MSH) has important host defense properties, in part similar to those of corticosteroids. Previous research suggests that secretion of alpha-MSH and of ACTH are controlled separately. The relationship between release of alpha-MSH and the activity of the hypothalamic-pituitary-adrenal axis in the rabbit was examined by monitoring changes in circulating alpha-MSH, ACTH, and corticosterone in response to endotoxin and corticotropin-releasing hormone (CRH), both with and without dexamethasone pretreatment. Endotoxin (1 microgram/kg IV) did not cause alpha-MSH release, but it did increase plasma concentrations of ACTH and corticosterone. Similarly, CRH (1 and 10 micrograms/kg IV) did not affect plasma alpha-MSH, whereas it stimulated ACTH and corticosterone release. Dexamethasone pretreatment abolished the responses of ACTH and corticosterone to either stimulus and did not modify circulating alpha-MSH after CRH. In contrast, dexamethasone pretreatment did result in a significant increase in plasma alpha-MSH after a dose of endotoxin that was ineffective alone. These data indicate that corticosteroids can facilitate the release of alpha-MSH, a powerful anti-inflammatory hormone. Since corticosteroids are released with certain challenges, this facilitatory activity may be important to the host response.

Melanocyte-stimulating hormone and persistent tardive dyskinesia: a hypothesis

An increased incidence of abnormal perioral movements has recently been reported in drug-naive pinealectomized rats with further accentuation of these movements following administration of haloperidol. Analysis of the temporal course of the development of the perioral dyskinetic movements revealed that the onset of these movements occurred within 4 days postoperatively and peaked at 3 weeks to plateau over the following 4-6 weeks. Increased pituitary Melanocyte-stimulating hormone (MSH) content has been reported in pinealectomized rats. Elevation of MSH content in the pinealectomized rats occurred within 3 days of surgery and was followed by normalization within 4 weeks. These findings suggest that compensatory mechanisms involving hypothalamic-pituitary MSH release must have been activated to induce normalization of pituitary MSH levels. Moreover, reduction of pituitary MSH levels may have coincided with attenuation in the severity of the perioral dyskinetic movements. It is possible that the development of tardive dyskinesia (TD) may in part be associated with increased brain and plasma MSH levels and that impaired hypothalamic-pituitary regulatory mechanisms of MSH release may be associated with persistent TD. The pineal gland may be implicated in this process as diminished melatonin secretion may be associated with disinhibition of MSH release. Thus, the above hypothesis complements and extends the recently presented "melatonin hypothesis" and suggests that research of pineal-hypothalamic interactions may be crucial to the further understanding of TD.

Antidiuretic hormone involvement in the release of alpha-melanocyte-stimulating hormone by hyperosmotic stimuli

In the normal Wistar rat, the plasma alpha-MSH level was raised by hypertonic saline injection (as compared with control rats injected with isotonic saline). No such rise in alpha-MSH followed hypertonic saline administration in the Brattleboro (hereditary diabetes insipidus) animal (compared to isotonic saline injected controls). It is suggested that, in the rat, endogenous antidiuretic hormone is involved in the secretory response of the pars intermedia to osmotic stimuli.

Pro-opiocortin: the multiple adrenal hormone precursor. Review

Corticotropin (ACTH) is biosynthesized in the human pituitary gland as a long polypeptide precursor (pro-opiocortin) of some 240 residues. When ACTH is secreted in response to stress, the peptides derived from the rest of this precursor, pro-gamma-melanotropin (gamma-MSH) and beta-lipotropin (beta-LPH), are also secreted (Fig. 1). This article will describe the search for a biological significance for this phenomenon.

Methionine enkephalin-induced changes in pigmentation of zebrafish (Cyprinidae, Brachydanio rerio) and related species and varieties, measured videodensitometrically. I. Zebrafish

The ability of MSH and of methionine enkephalin (met-E) to induce dispersion of pigment granules was examined in melanophores and in xanthophores of the zebrafish Brachydanio rerio using the melanophore index (MI) and videodensitometry. Both methods gave similar results. In B. rerio both MSH and met-E induced pigment dispersion in dermal melanophores, in fin and peritoneal melanophores, and in xanthophores. Darkening lasted a few hours. However, met-E-induced darkening developed 40-50 min later and faded more slowly than the effect of MSH. Both effects were dose related. Naloxone prevented met-E-induced darkening while it did not interfere with the MSH-induced effect. Epidermal melanophores did not react to either MSH or met-E. Thus met-E proved to induce changes of coloration when injected into a fish. Our data suggest a central mechanism involved in met-E-mediated change of coloration in zebrafish under the conditions examined. A new approach was suggested for objective measurement of the mean body darkness of the fish with the help of computational videodensitometry. Our fist results indicate a proportionality between the MI evaluation and videodensitometry.

Methionine enkephalin-induced changes in pigmentation of zebrafish (Cyprinidae, Brachydanio rerio) and related species and varieties, measured videodensitometrically. II. Pearl and gold danios

In the fish Brachydanio albolineatus (pearl danio) MSH-induced darkening was similar to that of the B. rerio (zebrafish). However, they showed a greatly reduced response to methionine enkephalin (met-E) though these fish apparently have normal dermal melanophores. This suggests a central nature of met-E-induced darkening and on the other hand at least a partial lack of MSH production and/or release in response to met-E in these fish. Therefore this reduction in the response to met-E may involve a partial lack of opiate receptors in the cells that provide or stimulate MSH production in the pearl danio. In the B. rerio gold mutant met-E appeared to be able to induce production and/or release of MSH, but these fish have almost no dermal melanophores (except a few in the dorsal and tail fins) and therefore show no darkening in response to either MSH or met-E.

Alpha-melanocyte-stimulating hormone and behavior

Melanocyte-stimulating hormone (MSH) has putative adaptive significance in all forms of species where it is present. In mammals the polypeptide chain influences learning, memory and attention. Chemically MSH shares the first 13 (alpha-MSH) or the first 18 or 22 (beta-MSH) amino acids with adrenocorticotropic hormone (ACTH), even though the mechanisms of secretion and behavioral effects are often quite different. The still shorter peptide chain MSH/ACH4-10 demonstrates significant melanotropic and behavioral actions of alpha-MSH without showing any steroidogenic effect. Behaviorally, alpha-MSH and MSH/ACTH analogues (MSH/ACTH4-9 and MSH/ACTH4-10 influence the parameters of learning, attention and memory in both human and infrahuman subjects. Alpha-MSH has also been reported to increase sensitivity and augment arousal mechanisms in the CNS. Alpha-MSH has been observed to increase and sustain novelty-induced defecation, and this behavior was found to be accompanied by a concomitant decrease in whole brain DA and NE levels in both intact and hypophysectomized rats exposed daily to a test box. The behavioral effects of alpha-MSH may be partially modulated by the enhanced cyclic-AMP activity in the CNS observed after MSH administration. MSH also seems to be working in conjunction with the hypothalamic tripeptide MIF-1 and the pineal hormone melatonin, both of which can affect the release of MSH from the pituitary. Recent evidence suggests that MSH is counterbalancing against and complementing with the effects of endorphins, specifically beta-endorphin (61-91 chain of beta-LPH), in maintaining learning and attentive behaviors.

Structure activity relationship studies with hypothalamic peptide hormones III. Effect of melanotropin-release inhibiting factor and analogs on tolerance to morphine in the rat

The effects of several analogs of melanotropin-release inhibiting factor (MIF, Pro-Leu-Gly-NH2) on the development of tolerance to the hyperthermic, hypothermic and cataleptic actions of morphine were investigated in male Sprague-Dawley rats. The analogs that were examined included. Pro-Gly-Gly-NH2 (I), Pro-VAl-Gly-NH2 (II), Pro-Leu-beta-Ala-NH2 (III), Pro-Leu-Gly-NHCH3 (IV), Pro-Leu-NH2 (V) and cyclo (Pro-Gly) (VI). Subcutaneous implantation of four morphine pellets (each containing 75 mg of morphine free base) during a 3-day period was used to develop tolerance to the pharmacological effects of morphine. Concurrent daily subcutaneous administration of any of the above peptides (I through VI) at a 10 mu mol/kg dose did not modify the development of tolerance to morphine-induced hyperthermia, hypothermia or catalepsy. The development of tolerance to morphine was, however, inhibited by equivalent doses of MIF. Treatment with these peptides did not alter the distribution of morphine in brain and plasma. It is concluded that the structural requirements for the inhibitory effect of MIF on the development of tolerance to morphine are very strict and that the following modifications in the structure of MIF result in the loss of activity (a) substitution of Gly or Val in place of Leu (b) replacement of Gly-NH2 with Gly-NHCH3 or beta-Ala-NH2 (c) removal of Gly, and (d) removal of Leu followed by cyclization of Pro-Gly.

Development of a radioimmunoassay for Pro-Leu-Gly-NH2 (PLG or MIF-I): evidence that PLG is not present in rat brain

Pro-Leu-Gly-NH2 (PLG), which is the C-terminal tripeptide tail of oxytocin, has been reported to possess melanocyte-stimulating hormone (MSH)-release-inhibiting activity. Although it has been isolated from bovine hypothalamus, little is known about the CNS distribution of this peptide in other species. In this report, we describe the development of a radioimmunoassay which can be used to measure both PLG and oxytocin following chromatographic separation by high pressure liquid chromatography (HPLC). Using this method, we are unable to demonstrate the presence of any endogenous PLG in rat hypothalamus, preoptic area, pituitary, or eye tissue. However, synthetic PLG, which is added to tissue homogenates as an internal standard, is consistently recovered from all areas. We conclude that the PLG tripeptide is not present in the rat brain and thus cannot be the physiological regulator of MSH secretion.

Modification of d-amphetamine- or chlorpromazine-induced hypothermia by beta-endorphin, MIF-I, and alpha-MSH: mediation by the dopaminergic system

The effects of beta-endorphin, MIF-I, and alpha-MSH on d-amphetamine- a CPZ-induced hypothermias in rats kept at 4 degrees C were tested in three experimental groups: (a) intact; (b) rats with lesions of the olfactory tubercle; and (c) rats in which the link between the DA mesolimbic pathway and the striatum was disconnected. All drugs tested alone (except MIF-I) caused significant hypothermia. Pretreatment with CPZ, MIF-I, and alpha-MSH potentiated d-amphetamine-induced hypothermia in intact rats. Pretreatment with alpha-MSH potentiated CPZ-induced hypothermia. beta-Endorphin partially blocked d-amphetamine-induced hypothermia, but did not interact with CPZ, MIF-I, or alpha-MSH. All potentiations were either reduced or disappeared in the incisioned rats. CPZ and alpha-MSH caused hypothermia in olfactory tubercle-lesioned rats. The results indicate that: (a) the DA mesolimbic pathway is involved in the hypothermic response of all drugs tested; (b) an intact feedback loop is required for the potentiation of the hypothermic response of CPZ on d-amphetamine, MIF-I on d-amphetamine, and alpha-MSH on d-amphetamine and CPZ; (c) beta-endorphin acts as a partial blocker of d-amphetamine; MIF-I is a weak potentiator of d-amphetamine, alpha-MSH acts as a negative modulator of the DA system, most probably in the striatum.

Distribution of opiate receptors in the monkey brain: an autoradiographic study

By employing both in vivo and in vitro labeling techniques, opiate receptors were labeled with tritiated diprenorphine in the monkey brain and localized by light microscopic autoradiography. Both methods of labeling gave similar results, allowing a description of discrete areas having opiate binding sites. High concentrations of opiate receptors were found in the substantia gelatinosa of the spinal cord, nucleus tractus solitarius, area postrema, lateral parabrachial nucleus, substantia grisea centralis, several nuclei of the thalamus and hypothalamus, substantia innominata and in the amygdala. In the monkey pituitary, receptors were found in the neurohypophysis. These results correlate well with those found in autoradiographic studies of the rat brain although there are a few notable differences. Many of the opiate receptor distributions can be correlated with anatomical loci of brain functions known to be influenced by administration of opiate compounds.

N-acetylation regulates the behavioral activity of alpha-melanotropin in a multineurotransmitter neuron

A multineurotransmitter neuronal system that synthesizes and secretes both acetylated and deacetylated forms of alpha-melantropin and beta-endorphin is present in rat and human brain. The N-acetylated from of alpha-melanotropin had more potent behavioral effects than the deacetylated alpha-melanotropin. In the case of beta-endorphin, however, the deacetylated form has been shown to be more potent than the acetylated form. Enzymatic N-acetylation appears to be an important regulatory process for modulating the behavioral activity of peptides secreted from the opiomelanotropinergic multineurotransmitter neuron.

Effects of beta-lipotropin and beta-lipotropin-derived peptides on aldosterone production in the rat adrenal gland

To investigate the role of non-ACTH pituitary peptides on steroidogenesis, we studied the effects of synthetic beta-lipotropin, beta-melanotropin, and beta-endorphin on aldosterone and corticosterone stimulation using rat adrenal collagenase-dispersed capsular and decapsular cells. beta-lipotropin induced a significant aldosterone stimulation in a dose-dependent fashion (10 nM-1 muM). beta-endorphin, which is the carboxyterminal fragment of beta-lipotropin, did not stimulate aldosterone production at the doses used (3 nM-6 muM). beta-melanotropin, which is the middle fragment of beta-lipotropin, showed comparable effects on aldosterone stimulation. beta-lipotropin and beta-melanotropin did not affect corticosterone production in decapsular cells. Although ACTH(1-24) caused a significant increase in cyclic AMP production in capsular cells in a dose-dependent fashion (1 nM-1 muM), beta-lipotropin and beta-melanotropin did not induce an increase in cyclic AMP production at the doses used (1 nM-1 muM). The beta-melanotropin analogue (glycine[Gly](10)-beta-melanotropin) inhibited aldosterone production induced by beta-lipotropin or beta-melanotropin, but did not inhibit aldosterone production induced by ACTH(1-24) or angiotensin II. Corticotropin-inhibiting peptide (ACTH(7-38)) inhibited not only ACTH(1-24) action but also beta-lipotropin or beta-melanotropin action; however it did not affect angiotensin II-induced aldosterone production. (saralasin [Sar](1); alanine [Ala](8))-Angiotensin II inhibited the actions of beta-lipotropin and beta-melanotropin as well as angiotensin II. These results indicate that (a) beta-lipotropin and beta-melanotropin cause a significant stimulation of aldosterone production in capsular cells, (b) beta-lipotropin and beta-melanotropin have a preferential effect on zona glomerulosa cells, (c) beta-melanotropin contains the active peptide core necessary for aldosterone stimulation, (d) the effects of these peptides on aldosterone production may be independent of cyclic AMP, and (e) the receptors for beta-lipotropin or beta-melanotropin may be different from those for ACTH or angiotensin II.

alpha-MSH, MIF-I and melatonin: effects on novelty-induced defecation, plasma 11-OHCS and central catecholamines in rats

The pituitary-hypothalamo-pineal complex involving MSH, MIF-I and melatonin has been strongly emphasized in the adaptive mechanism of the animal. A series of experiments was conducted to investigate the effects of alpha-MSH, MIF-I and melatonin on novelty-induced defecation, step-down activity, plasma 11-OHCS levels and whole brain DA and NE concentrations over days of novelty X drug treatment. alpha-MSH consistently enhanced and sustained novelty-induced defecation, increased plasma 11-OHCS levels in the resting intact rats and in the novelty exposed hypophysectomized (hypox) rats, and decreased brain DA and NE levels in intact, hypox and sham-hypox rats. MSH did not increase plasma 11-OHCS in intact and sham-hypox rats during exposure to novelty. MIF-I significantly habituated novelty-induced defecation and increased brain DA and NE levels over 5 days of drug X novelty treatment. Melatonin, on the other hand, inhibited novelty-induced defecation, decreased plasma 11-OHCS and increased brain DA level over 5 days of melatonin X novelty treatment. MSH, MIF-I or melatonin did not show any significant effect on the step-down activity of the rats. The results suggest the possibility that central CAs may be implicated in the behavioral changes observed after alpha-MSH, MIF-I and melatonin administration and in the interaction of the pituitary-hypothalamo-pineal complex involving MSH, MIF-I and melatonin.

Evidence that N-acetylation regulates the behavioral activity of alpha-MSH in the rat and human central nervous system

alpha-MSH immunoreactive peptides were fractionated and characterized in rat and human brain and rat pituitary by reversed phase high pressure liquid chromatographic techniques. alpha-MSH and deacetylated alpha-MSH were two major naturally existing peptides in both brain and pituitary gland. Subsequent experiments examined the roles of these two peptides in neuronal function. The alpha-MSH was clearly more effective than deacetylated alpha-MSH in improving performance on a visual discrimination task after intraperitoneal administration and in inducing excessive grooming after intraventricular administration. The difference in behavioral potency may be explained by the fact that alpha-MSH was much more resistant to peptidase degradation than was deacetylated alpha-MSH. N-acetylation of alpha-MSH may be an effective regulatory process for modulating the behavioral potency of the secretory product of alpha-MSH-containing pituitary cells and neurons.

alpha-MSH effects on novelty-induced defecation, plasma 11-OHCS and whole brain catecholamines in hypophysectomized rats

The effect of hypophysectomy on novelty-induced defecation was found to be inhibitory in nature, but this effect was reversed by treatment with alpha-MSH. MSH-treated hypox rats maintained, over days, novelty-induced defecation and showed a significant elevation in plasma 11-OHCS levels, compared with the levels of control-injected counterparts. MSH treatment also reduced over Days 1 to 5 the whole brain DA and whole brain NE levels in hypox animals. Control-treated hypox rats, however, showed an increase in brain NE concentration which was significantly reduced by MSH treatment. Sham-hypox animals also sustained novelty-induced defecation after MSH treatment but did not show a significant rise in plasma 11-OHCS level. Whole brain DA and whole brain NE levels in sham-hypox rats were also reduced significantly by MSH treatment. The behavioral maintenance of defecation in hypox and sham-hypox rats seem to be concomitant with significant reductions in whole brain catecholamines.

Changes in opiate activity of rat pituitary following acute administration of neuroleptics

An increase was found in the opiate activity of pituitary extracts obtained rom rats injected with the neuroleptic drugs trifluoperazine and sulpiride. The increase of opiate activity, measured by bioassay, was particularly evident 2 h after the administration of sulpiride. Dexamethasone completely prevented the neuroleptic-induced effect. Trifluoperazine and sulpiride may have affected dopaminergic mechanisms regulating endorphin storage in the pituitary.

Effects of alpha-MSH and melatonin on passive avoidance and on PA-induced defecation and plasma 11-OHCS in hypophysectomized rats

The present study shows tha alpha-MSH facilitates the acquisition and delays the extinction of a Passive Avoidance Response (PAR) in the hypox animals. MSH exacerbates PA-induced defecation in both hypox and sham-hypox animals. Hypox and sham-hypox animals treated with MSH do not differ on PAR or on PA-induced defecation. Melatonin, on the other hand, has no significant effect on PAR in hypox rats, but retards acquisition and facilitates extinction of the PAR in sham-hypox rats. Melatonin also inhibits PA-induced defecation in sham-hypox rats. Sham-hypox and hypox rats treated with Melatonin do not differ on PAR learning, retention (Extinction) and PA-induced defecation. MSH and Melatonin also seem to have opposite effects on plasma 11-OHCS levels measured at the end of PAR extinction. MSH increases plasma 11-OHCS in hypox rats, whereas Melatonin decreases plasma 11-OHCS in sham-hypox rats. Melatonin does not lower further the very low level of plasma 11-OHCS in hypox rats.

Interaction of MIF-I or alpha-MSH with D-amphetamine or chlorpromazine on thermoregulation and motor activity of rats maintained at different ambient temperatures

Administration of several doses of MIF-I or alpha-MSH did not modify colonic temperature or the level of motor activity of rats in ambient temperatures of 4 degree or 20 degrees C. However, the thermoregulatory but not motor effects of the interaction between MIF-I or alpha-MSH with d-amphetamine were dependent upon ambient temperature. At 4 degree C, 1.0 mg/kg of both peptides enhanced the d-amphetamine-induced hypothermia, but at 20 degrees C both peptides blocked the hyperthermic effects of d-amphetamine. The hypothermic effect of chlorpromazine (CPZ) at 4 degree C and 20 degrees C was blocked by 1.0 mg/kg MIF-I but not by 1.0 mg/kg alpha-MSH. No linear dose response relationships between various doses of MIF-I or alpha-MSH and thermal responses were found. Administration of melanin or the use of hypophysectomized rats did not alter the significant interactions observed after peripheral injections.

Plasma concentrations of alpha-melanotropin in the rat during the acquisition and extinction of conditioned avoidance behaviour and during the acquisition of maze learning behaviour

Concentrations of immunoassayable alpha-melanotropin in plasma were increased above control levels during the acquisition of conditioned avoidance behaviour but not during the extinction of this behaviour. There were no significant variations in levels of alpha-melanotropin in plasma during the acquisition of reward motivated maze learning behaviour. Throughout the latter test hormone concentrations were increased above normal levels. Non-specific stress was thought to be an important factor in the production of increases in concentrations of alpha-melanotropin in plasma. Acute physical stress, such as that caused by the electric foot shock of the avoidance studies, produced the greatest increases, while the smaller increase noted during maze learning was attributed to the stress of the chronic food deprivation schedule used in this test. The data did not support a role for systemic melanotropin in the processes of learning and memory as there were no consistent correlations between levels of alpha-melanotropin in plasma and the parameters of learning in the tests. Although a role for stress-induced alpha-melanotropin release from the pituitary gland in the enhancement of attention was thought possible, actions of exogenous melanotropins on behaviour could be due to effects on melanotropin-containing systems present within the central nervous system.

Effects of MIF-I and melatonin on novelty-induced defecation and associated plasma 11-OHCS and brain catecholamines

In two experiments the effects were investigated of MSH-inhibiting factor-I (MIF-I) and of Melatonin on step-down latencies, defection, plasma 11-OHCS levels, whole brain DA and whole brain NE concentrations on Days 1, 3 and 5 of novelty exposure. Treatment with MIF-I led to a significant habituation of novelty-induced defecation over 5 days, whereas plasma 11-OHCS level was reduced only on Day 1. The concentrations of whole brain DA and whole brain NE also showed a significant increase over days of MIF-I and novelty treatment. Melatonin treatment, on the other hand, significantly inhibited novelty-induced defecation and reduced plasma 11-OHCS level on Day 5 of novelty exposure. Melatonin treatment led to a significant increase of whole brain DA in animals exposed to novelty for 5 days. Neither MIF-I nor Melatonin was found to significantly affect the step-down activity of treated animals. The overall results suggested a possible relationship between novelty-induced defecation and brain DA levels of MIF-I and Melatonin treated animals.

Serotonin and MSH secretion: effect of parachlorophenylalanine on the pituitary cytology of the eel

Parachlorophenylalanine (pCPA), an inhibitor of tryptophan hydroxylase which depletes brain serotonin in higher vertebrates, was injected into freshwater eels. After 4 or 6 injections (200 mg/kg/day) or 10 injections (100 and 140 mg/kg/day), the animals are paler, with a low melanophore index. In the pituitary gland, granules tend to accumulate in the basal part of the MSH cells and in the perinuclear area. Cells appear smaller with a decreased nuclear area (P less than 0.001). In the neurohypophysis, the amount of neurosecretory material is often reduced. Conversely, injections of 5-hydroxytryptophan induce a strong darkening, a result similar to that previously reported in some amphibian species and in one lacertilian species. These data substantiate the hypothesis of a stimulatory influence of 5-hydroxytryptamine on MSH release and possibly its synthesis in the eel and other lower vertebrates.

Phenothiazine therapy and plasma immunoreactive beta-MSH in schizophrenia and pruritic dermatoses

Plasma immunoreactive beta-melanocyte-stimulating hormone (beta-MSH) concentrations were normal in schizophrenic patients on prolonged and high dosage phenothiazine therapy. A group of patients treated with chlorpromazine 25 mg three times daily for pruritic dermatoses also showed no significant change in plasma beta-MSH concentration.

Effects of handling and etherization on incorporation of [3H] lysine into protein of mouse brain and liver

A standardized handling experience of 20 sec duration elevated the amount of radioactive lysine incorporated into brain total proteins during a 10 min labeling period begun either 10 min or 30 min after the handling. Etherization for 20 sec produced similar metabolic changes. Incorporation of [3H] lysine into liver proteins was minimally affected by handling, while slightly altered by etherization. The metabolic changes detected in the brain after handling did not appear to be side-effects of changes in blood-borne radioactivity. The results indicate that laboratory stresses often thought to be of minor importance can have large effects on ordinary assays of protein metabolism in brain.